PMID- 32975211
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20240204
IS  - 0219-1032 (Electronic)
IS  - 1016-8478 (Print)
IS  - 1016-8478 (Linking)
VI  - 43
IP  - 9
DP  - 2020 Sep 30
TI  - Peroxiredoxin 3 Has Important Roles on Arsenic Trioxide Induced Apoptosis in 
      Human Acute Promyelocytic Leukemia Cell Line via Hyperoxidation of Mitochondrial 
      Specific Reactive Oxygen Species.
PG  - 813-820
LID - 10.14348/molcells.2020.2234 [doi]
AB  - NB4 cell, the human acute promyelocytic leukemia (APL) cell line, was treated 
      with various concentrations of arsenic trioxide (ATO) to induce apoptosis, 
      measured by staining with 7-amino-actinomycin D (7-AAD) by flow cytometry. 2', 
      7'-dichlorodihydro-fluorescein-diacetate (DCF-DA) and MitoSOX(TM) Red 
      mitochondrial superoxide indicator were used to detect intracellular and 
      mitochondrial reactive oxygen species (ROS). The steady-state level of SO(2) 
      (Cysteine sulfinic acid, Cys-SO(2)H) form for peroxiredoxin 3 (PRX3) was measured 
      by a western blot. To evaluate the effect of sulfiredoxin 1 depletion, NB4 cells 
      were transfected with small interfering RNA and analyzed for their influence on 
      ROS, redox enzymes, and apoptosis. The mitochondrial ROS of NB4 cells 
      significantly increased after ATO treatment. NB4 cell apoptosis after ATO 
      treatment increased in a time-dependent manner. Increased SO(2) form and dimeric 
      PRX3 were observed as a hyperoxidation reaction in NB4 cells post-ATO treatment, 
      in concordance with mitochondrial ROS accumulation. Sulfiredoxin 1 expression is 
      downregulated by small interfering RNA transfection, which potentiated 
      mitochondrial ROS generation and cell growth arrest in ATO-treated NB4 cells. Our 
      results indicate that ATO-induced ROS generation in APL cell mitochondria is 
      attributable to PRX3 hyperoxidation as well as dimerized PRX3 accumulation, 
      subsequently triggering apoptosis. The downregulation of sulfiredoxin 1 could 
      amplify apoptosis in ATO-treated APL cells.
FAU - Mun, Yeung-Chul
AU  - Mun YC
AUID- ORCID: 0000-0002-1882-3983
AD  - Department of Hematology and Oncology, Ewha Womans University College of 
      Medicine, Seoul 07985, Korea.
FAU - Ahn, Jee Young
AU  - Ahn JY
AUID- ORCID: 0000-0002-9813-0481
AD  - Department of Hematology and Oncology, Ewha Womans University College of 
      Medicine, Seoul 07985, Korea.
FAU - Yoo, Eun Sun
AU  - Yoo ES
AUID- ORCID: 0000-0001-6419-2337
AD  - Department of Pediatrics, Ewha Womans University College of Medicine, Seoul 
      07985, Korea.
FAU - Lee, Kyoung Eun
AU  - Lee KE
AUID- ORCID: 0000-0003-1596-8666
AD  - Department of Hematology and Oncology, Ewha Womans University College of 
      Medicine, Seoul 07985, Korea.
FAU - Nam, Eun Mi
AU  - Nam EM
AUID- ORCID: 0000-0003-0108-5352
AD  - Department of Hematology and Oncology, Ewha Womans University College of 
      Medicine, Seoul 07985, Korea.
FAU - Huh, Jungwon
AU  - Huh J
AUID- ORCID: 0000-0001-8758-9847
AD  - Department of Laboratory Medicine, Ewha Womans University College of Medicine, 
      Seoul 07985, Korea.
FAU - Woo, Hyun Ae
AU  - Woo HA
AUID- ORCID: 0000-0002-3483-1203
AD  - Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, 
      Korea.
FAU - Rhee, Sue Goo
AU  - Rhee SG
AUID- ORCID: 0000-0002-4740-4956
AD  - Yonsei Biomedical Research Institute, Yonsei University College of Medicine, 
      Seoul 03722, Korea.
FAU - Seong, Chu Myong
AU  - Seong CM
AUID- ORCID: 0000-0001-9985-9218
AD  - Department of Hematology and Oncology, Ewha Womans University College of 
      Medicine, Seoul 07985, Korea.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Mol Cells
JT  - Molecules and cells
JID - 9610936
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Reactive Oxygen Species)
RN  - EC 1.11.1.15 (Peroxiredoxin III)
RN  - S7V92P67HO (Arsenic Trioxide)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Apoptosis/drug effects
MH  - Arsenic Trioxide/*pharmacology
MH  - Cell Line, Tumor
MH  - Humans
MH  - Leukemia, Promyelocytic, Acute/*drug therapy/metabolism/pathology
MH  - Mitochondria/*metabolism
MH  - Peroxiredoxin III/*metabolism
MH  - Reactive Oxygen Species/metabolism
MH  - Transfection
PMC - PMC7528683
OTO - NOTNLM
OT  - acute promyelocytic leukemia
OT  - arsenic trioxide
OT  - peroxiredoxin 3
COIS- CONFLICT OF INTEREST The authors have no potential conflicts of interest to 
      disclose.
EDAT- 2020/09/26 06:00
MHDA- 2021/06/25 06:00
PMCR- 2020/09/30
CRDT- 2020/09/25 08:36
PHST- 2019/10/15 00:00 [received]
PHST- 2020/08/24 00:00 [revised]
PHST- 2020/08/25 00:00 [accepted]
PHST- 2020/09/25 08:36 [entrez]
PHST- 2020/09/26 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
PHST- 2020/09/30 00:00 [pmc-release]
AID - S1016-8478(23)00343-6 [pii]
AID - molce-43-813 [pii]
AID - 10.14348/molcells.2020.2234 [doi]
PST - ppublish
SO  - Mol Cells. 2020 Sep 30;43(9):813-820. doi: 10.14348/molcells.2020.2234.